NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all persons or entities who purchased or otherwise acquired BioAge Labs, Inc. (“BioAge” or the “Company”) (NASDAQ: BIOA) securities on BioAge Labs’ initial public offering (the “IPO”) held on September 26, 2024, inclusive (the “Class Period”). The lawsuit seeks to recover damages for the ...

NEWTOWN, Pa., Jan. 8, 2025 /PRNewswire/ -- Edelson Lechtzin LLP, a leading class action law firm, is investigating securities fraud claims on behalf of all investors of BioAge Labs, Inc. (NASDAQ: BIOA) who purchased stock pursuant and/or traceable to BioAge Labs' registration statement issued in connection with the company's initial public offering (the "IPO") on September 26, 2024. To join this case, go HERE.Investors who purchased BioLabs stock may move the U.S. District Court for the Northern of Californ ...

SAN DIEGO, Jan. 8, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of BioAge Labs, Inc. (NASDAQ: BIOA) stock pursuant and/or traceable to BioAge Labs' registration statement issued in connection with BioAge Labs' initial public offering (the "IPO") held on September 26, 2024, have until March 10, 2025 to seek appointment as lead plaintiff of the BioAge Labs class action lawsuit.  Captioned Soto v. BioAge Labs, Inc., No. 25-cv-00196 (N.D. Cal.), th ...

NEW YORK, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against BioAge Labs, Inc. (“BioAge” or the “Company”) (NASDAQ: BIOA) in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or otherwise acquired BioAge securities pursuant and/or traceable to BioAge’s registration statement for the initial public offering hel ...

SAN FRANCISCO, Jan. 3, 2025 /PRNewswire/ -- Shares of BioAge (NASDAQ: BIOA) have plummeted since the company's December 6 announcement of the discontinuation of a Phase 2 trial for its weight-loss drug azelaprag due to safety concerns. The abrupt halt comes just a little over two months after the company raised $198 million in a highly anticipated initial public offering in late September.Hagens Berman has opened an investigation into whether BioAge's IPO documents may have contained misstatements or omissi ...

NEW YORK, Dec. 27, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  BioAge Labs, Inc. ("BioAge" or the "Company") (NASDAQ: BIOA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether BioAge and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On or around September 26 ...

BOSTON, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Block & Leviton is investigating BioAge Labs, Inc. (NASDAQ:BIOA) for potential securities law violations. Investors who have lost money in their BioAge Labs, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/bioa. What is this all about? Shares of BioAge Labs, Inc. were down 73% on December 9, after the company discontinued its STRIDES Phase 2 trial for azelaprag, c ...

BOSTON, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Block & Leviton is investigating BioAge Labs, Inc. (Nasdaq: BIOA) for potential securities law violations. Investors who have lost money in their BioAge Labs, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/bioa. What is this all about? Shares of BioAge Labs, Inc. were down 73% on December 9, after the company discontinued its STRIDES Phase 2 trial for azelaprag, ...

Core Viewpoint - BioArctic AB has entered into a global exclusive license agreement with Bristol Myers Squibb for its PyroGlutamate-amyloid-beta antibody program, which includes significant financial terms and the potential for future collaboration in neuroscience treatments [1][2]. Group 1: Agreement Details - The agreement grants Bristol Myers Squibb exclusive rights for the development and commercialization of BAN1503 and BAN2803 globally, with BioArctic receiving an upfront payment of USD 100 million and up to USD 1.25 billion in milestone payments [1][2]. - BioArctic will also receive tiered low double-digit royalties on global product sales and retains an option to co-commercialize the products in the Nordic region [2]. Group 2: Technology Overview - BioArctic's PyroGlu-Aβ antibody program targets a specific truncated form of amyloid-beta, which is associated with Alzheimer's disease and leads to harmful aggregates affecting cognitive function [3]. - The BrainTransporter technology, included in BAN2803, aims to enhance the delivery of biotherapeutics across the blood-brain barrier by utilizing the transferrin receptor, potentially improving drug efficacy and safety [4][8]. Group 3: Company Background - BioArctic is a Swedish biopharma company focused on innovative treatments for neurodegenerative diseases, including the development of Leqembi, the first drug shown to slow Alzheimer's progression [9]. - The company has a diverse research portfolio targeting various neurodegenerative conditions, leveraging its proprietary BrainTransporter technology for enhanced treatment delivery [9].

Collaboration will leverage BioAge's differentiated human longevity data and platform and Novartis expertise in the biology of physical exercise to identify drug targets to treat diseases related to aging Novartis to pay up to $20M comprising upfront payments and research funding; BioAge may receive up to $530M in future long-term research, development, and commercial milestones RICHMOND, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge"), a clinical-stage biopharmaceutical company devel ...